# Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Source: https://onco.cc/trials/nct04595565/  
OnCo record `nct04595565` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of capecitabine, carboplatin, cisplatin and sacituzumab govitecan in triple-negative breast cancer, run by GBG Forschungs GmbH, active but no longer recruiting.

## Summary

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer. ClinicalTrials.gov record last updated 2026-04-22: active not recruiting. Enrollment is planned at 1332 participants. Primary completion is estimated at 2027-03-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Capecitabine, Carboplatin, Cisplatin, Sacituzumab govitecan. Registered primary measures: Invasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice..

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Also known as: SASCIA
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04595565
- Phase: 3
- Setting: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
- Sponsor: GBG Forschungs GmbH
- Enrolled: 1332

## Notes

- ClinicalTrials.gov record last updated 2026-04-22: active not recruiting. Enrollment is planned at 1332 participants. Primary completion is estimated at 2027-03-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT04595565: https://clinicaltrials.gov/study/NCT04595565

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- companies: [German Breast Group (GBG)](https://onco.cc/companies/gbg/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04595565.json